Pharmacy Healthcare Solutions Inc. (PHSI) consults with pharmaceutical manufacturers, PBMs, retail pharmacy chains, and software companies on strategic business and marketing issues. Consulting projects across these market segments provide PHSI with the latest information on emerging trends as well as new products and services. Our consultants have extensive retail, mail service and managed care experience to create actionable recommendations for our clients’ challenging business issues.
PHSI Vice President Don Dietz will be attending the PQA Annual Meeting in Arlington, VA on May 18-20, 2016. If you will be attending the meeting and would like to schedule a time to meet with Don, click here to contact PHSI.
PHSI will be attending the NCPDP Annual Technology & Business Conference on May 1-4, 2016 and the 2016 Armada Specialty Pharmacy Summit on May 3-5, 2016.
PHSI President Tim Kosty and Vice President Don Dietz contributed to the January/February 2016 edition of ComputerTalk for the Pharmacist. In their Viewpoints article, Tim and Don review the market dynamics driving the accelerating consolidation of retail pharmacies and the impact that consolidations have on various stakeholders in the industry. Click here to read their Read More →
The National Prescription Drug Take-Back Day sponsored by the Drug Enforcement Administration (DEA) is scheduled for Saturday, April 30, 2016 from 10:00 am to 2:00 pm at participating locations. Visit the DEA website at http://www.deadiversion.usdoj.gov/drug_disposal/takeback to find a disposal site near you. Bring your unused, expired, and unwanted medication to a site near you. It Read More →
Pharmacists’ services continue to expand as pharmacists are getting involved in prescribing and/or furnishing certain medications, such as hormonal contraceptives, in several states. Listed below is the latest information on initiatives underway in Oregon and California. Oregon Pharmacists in Oregon can now prescribe and dispense hormonal contraceptives, both oral and transdermal. While the Oregon Board Read More →
2015 was a banner year for novel drugs approved. There were 45 novel drugs approved as new molecular entities (NME) under New Drug Applications (NDAs) or Biologics License Applications (BLAs) in 2015, up from 41 novel drugs approved in 2014. As a comparison, the FDA has averaged 28 novel drug approvals per year in the Read More →